Navigation Links
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
Date:5/20/2009

psule formulation, greater efficacy and reduced side effects.
  • Sales of Sinobiopharma's formulation of L-alanyl-L-glutamine for parenteral (intravenous) nutrition are projected to exceed 30,000 units in 2009.
  • The Company is in the process of submitting its application for approval of Rocuronium bromide, a next generation skeletal muscle relaxant that is also the first that can be stored at room temperature, to the Chinese Food and Drug Administration (SFDA).

  • "In the first quarter of 2009, we saw strong demand for our existing products," said Lequn Huang, Company President and CEO. "We expect that increased marketing efforts and expanded distribution will help boost additional growth for the rest of 2009, with projected improvements in both margins and profitability."

    About Sinobiopharma

    Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

        Contacts:
        Sinobiopharma, Inc.
        Investor Relations: 1-877-568-0188
    

    FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or resu
    '/>"/>

    SOURCE Sinobiopharma, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
    2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
    3. Sinobiopharma, Inc. Appoints New Director of Marketing
    4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
    5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
    6. Sinobiopharma Secures Rights to Seven Key Patents
    7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
    8. SemBioSys updates Apo AI development program
    9. Strategic Diagnostics Updates Roth Conference Presentation Time
    10. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
    11. SGX Pharmaceuticals Updates Date of Presentation at the BIO InvestorForum 2007
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
    (Date:8/21/2014)... , Aug. 21, 2014  Four-dimensional (4-D) ... behaviors based on external stimuli such as changes ... have a disruptive effect in multiple industries.  In ... business landscape by printing objects ranging from human ... automotive sectors. Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
    (Date:8/21/2014)... SoundConnect , a unified ... one of the nation’s Fastest Growing Private Companies ... 2nd consecutive year. Inc. magazine today ranked SoundConnect ... an exclusive ranking of the nation's fastest-growing private ... at the most important segment of the economy—America’s ...
    (Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
    Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
    ... Calif., Nov. 16, 2010 AVANIR Pharmaceuticals, ... it intends to offer and sell shares of its common ... is acting as sole book-running manager in the offering and ... Partners, and Merriman Capital are acting as co-managers for the ...
    ... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
    ... TRIANGLE PARK, N.C., Nov. 16, 2010 Scientists ... data demonstrating that the company,s lipid-conjugated drugs, ... human Organic Anion Transporters (hOATs) and thus have ... mechanism.  These data, presented at the International Pharmaceutical ...
    Cached Biology Technology:AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Intel Corporation acquires Toronto start-up CognoVision 2Intel Corporation acquires Toronto start-up CognoVision 3Intel Corporation acquires Toronto start-up CognoVision 4Intel Corporation acquires Toronto start-up CognoVision 5Intel Corporation acquires Toronto start-up CognoVision 6Intel Corporation acquires Toronto start-up CognoVision 7Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4
    (Date:8/20/2014)... population-based screening outcomes of approximately 3 million infants, a ... at the University of Massachusetts Medical School, have shown ... be successfully implemented across public health newborn screening programs. ... Aug. 20 issue of the Journal of the ... rate of SCID in newborns is higher than previously ...
    (Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
    (Date:8/20/2014)... causes a burning spiciness that is irresistible to some, ... effect are using their findings to develop a new ... be caused by inflammation or other problems. They reported ... in clinical trials, in ACS, Journal of Medicinal ... decades ago, scientists had pegged a compound called capsaicin ...
    Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
    ... ,   SPO (SPOM.OB), a leading ... that it has entered into an Investment Agreement,with Dutchess Opportunity ... Under the terms of the signed agreement, for a ... and Dutchess the,obligation to purchase common stock at a 6% ...
    ... experts from the outside to develop a new energy source ... acknowledge the need to innovate collaboratively if they are to ... NineSigma, the leading provider of Open Innovation and ... organizations is greater than ever, and can make a difference ...
    ... Lithuania, July 28, 2011 Neurotechnology , ... announced that MegaMatcher and VeriFinger SDK fingerprint compression ... means that the FBI has certified that these ... Scalar Quantization (WSQ) Gray-Scale Fingerprint Image Compression Specification, ...
    Cached Biology News:SPO Secures Equity Line Facility of US$5 Million 2SPO Secures Equity Line Facility of US$5 Million 3SPO Secures Equity Line Facility of US$5 Million 4NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 2NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 3NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 4MegaMatcher and VeriFinger SDK Fingerprint Compression Algorithms Receive WSQ Certification from FBI Biometric Center of Excellence 2MegaMatcher and VeriFinger SDK Fingerprint Compression Algorithms Receive WSQ Certification from FBI Biometric Center of Excellence 3
    Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
    CD45/CD34 combination 50 tests...
    WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
    Biology Products: